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We describe an infant presenting with contractures of the ﬁngers, a large ventricular septal defect (VSD), and severe pulmonary
artery dilatation. He had clinical and echocardiographic features of both neonatal or infantile Marfan syndrome (MFS) and
congenital contractural arachnodactyly. After surgical VSD closure, the aortic root developed progressive dilatation while the
size of pulmonary artery returned to normal limits. Eventually the diagnosis of MFS was conﬁrmed by DNA analysis.
1.Introduction
In infancy the diagnosis of Marfan syndrome may be
diﬃcult,andclinicalpresentationandprognosisarevariable.
We present a special case of infantile Marfan syndrome with
a congenital heart disease.
2. ClinicalPresentation
Our patient is a boy born to healthy parents (father is 37
years old, mother is 29 years old), who lives in Surinam.
The pregnancy was uneventful, and he was born at a normal
term. He had two healthy sisters of 6 and 9 years old. Family
history was noncontributory. At the age of 4 months he
developed heart failure and echocardiographic examination
showed a large ventricular septal defect (VSD) and atrial
septal defect (ASD) secundum type. The patient was sent to
our institution for cardiac surgery at the age of 8 months.
Physical examination showed a tall and dystrophic boy with
a height of 75.0cm (+1.5 SDS), weight of 5.5kg (<−2.5
SDS), and an arm span of 72.0cm (ratio arm span/height
is 0.96). His target height is 187cm (+0.4 SDS). He had
no distinguished facial anomalies with a normal palate and
normalears.Hehadapectuscarinatum,arachnodactyly,and
contractures of both proximal interphalanges of the third
and fourth digits. He was dyspnoeic and tachypnoeic, and
cardiac examination showed a hyperdynamic precordium,
ﬁxed splitting of the second heart sound, and no cardiac
murmurs. Echocardiography showed a secundum-type ASD
and a 17mm muscular inlet VSD with a large left- to-
right shunt causing pulmonary ﬂow hypertension. The right
atrium and right ventricle were dilated. Both mitral valve
(MV) and tricuspid valve (TV) had a mild prolapse with
a normal function. The pulmonary valve (PV), trunk, and
branches were severely dilated with the diameter of the
main pulmonary artery of 27.5mm (Table 1 and Figure 1).
The tricuspid aortic valve (AoV) showed normal function,
and the aortic root diameter was dilated (Table 1). Surgical
correction included primary closure of the ASD and closure
of the VSD with a Gore-Tex patch. The postoperative course
was uneventful with prompt recovery. Based on the clinical
and echocardiographic features the diﬀerential diagnosis
consisted of congenital contractural arachnodactyly (CCA)
and neonatal or infantile Marfan syndrome (MFS). At that2 Case Reports in Medicine
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Figure 1: Parasternal short-axis view of the pulmonary valve (PV)
and main pulmonary artery (MPA) of the patient preoperatively
(a) and directly postoperatively (b). The severe dilatation of the PV
(diameter 22mm) and MPA (diameter 27mm) diminished directly
postoperatively, almost to normal limits (17.4mm and 21.2mm,
resp.). RA: right atrium; RVOT: right ventricle outﬂow tract; Ao:
aorta.
time no further gene testing was performed. After recovery
the patient went home to Surinam, where the followup
continued up to an age of 6 years.
Duringfollowuphisheightwasexcessive(SDS > 2.5),the
contracturesoftheﬁngerswereprogressive,andhewaswear-
ing glasses because of myopia. Psychomotor development
was normal. Interestingly, echocardiographic examinations
showed signiﬁcant decrease of diameters of the pulmonary
valve and main pulmonary artery directly after operation
which remained within normal limits during followup
(Table 1, Figure 1). However, the diameter of the aortic
root increased from 22 to 23.4mm directly after operation
and with progressive dilatation to 38.7mm during followup
(Table 1, Figure 2). Thus far, aortic valve function remained
normal. The mild prolapse of the mitral valve remained
stablewithtrivialmitralregurgitation.Becauseofprogressive
aorticrootdilatationbeta-blockingtherapywasstartedatthe
age of 5 years.
At that time-gene testing was performed to further
diﬀerentiate between infantile MFS and CCA. Using dena-
turing high-performance liquid chromatography (DHPLC),
multiplexligation-dependentprobeampliﬁcation(MLPAkit
P065/P066 v3), and DNA sequence-analysis in 2008, we
foundaframeshiftmutationencodingastop-mutationinthe
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Figure 2: Parasternal long-axis view of left ventricle (LV) shows
severe dilatation of the aortic root at the age of almost 4 years.
Diameter of the aortic root is 32.2mm. LA: left atrium; LV: left
ventricle; RV: right ventricle; Ao: aorta.
FBN1 gene c.3396delA (p.Glu1133ArgfsX29) conﬁrming the
diagnosis of infantile Marfan syndrome.
3. Discussion
In infancy, the diagnosis of MFS can be diﬀerentiated in
neonatal MFS, severe infantile MFS or early-onset form of
MFS, and infants with a positive family mutation without
major features at that moment. Diﬀerentiation is important
because treatment and prognosis will be diﬀerent, but this
may be diﬃcult [2–6]. Marfan syndrome is an autosomal
dominant inherited disorder of connective tissue in which
ocular, skeletal, cardiovascular, integumentary, pulmonary,
and neurological features may be present in a highly variable
degree [7–9]. The diagnosis is still a clinical one, based on
fulﬁllmentofdiagnosticcriteria[10].Itiscausedbymissense
mutations in FBN1 gene [11] on chromosome 15q21.1,
the gene encoding ﬁbrillin-1, a principle component of
extracellular matrix microﬁbrils. A Marfan-like phenotype
can be caused by mutations in the TGFBR2 gene on
chromosome 3, encoding TGF-beta receptor 2 [12]. In the
classic form of Marfan syndrome, isolated occurrence is in
25–35% of the patients. Fibrillin indirectly controls TGF-
beta activation, and dysregulation of TGF-beta may play a
role in the pathophysiology of Marfan syndrome [13–23].
Maincardiovascularfeaturesareaorticrootdilatationand/or
aorta dissection and MV prolapse. Prognosis is mainly
determined by progressive aortic root dilatation, potentially
resulting in dissection and rupture. Prophylactic aortic root
repair has raised the life expectancy by 30 years or more
[24, 25].
Neonatal Marfan syndrome is a diﬀerent group of
patients with 50% mortality before the ﬁrst year of life
caused by heart failure. The deﬁnition of neonatal Marfan
syndrome is an estimated diagnosis before 3 months of age,
congenital pulmonary emphysema, severe atrioventricular
valve (TV and MV) regurgitation in combination with
congenital arachnodactyly, contractures, megalocornea, iri-
dodonesis, rocker bottom feet, crumpled ears, and loose skinCase Reports in Medicine 3
Table 1: Aortic root diameters and pulmonary artery diameters during followup.
Age
(yr)
Height
cm (SDS)
Weight
(SDS)
BSA
(m2)
Aortic root
mm (z-score)
PV
mm (z-score)
MPA
mm (z-score)
0.7 75.0 (+1.5) 5.5 (<−2.5) 0.34 22.0 (+8.6) 22.0 (+6.2) 27.5 (+8)
0.8 75.1 (+1.5) 5.6 (<−2.5) 0.34 23.4 (+9.2) 17.4 (+4.0) 21.2 (+6)
3.7 114.7 (>+2.5) 16.0 (<−2.5) 0.73 32.3 (+8.4) 20.0 (+1.9) 21.0 (+2)
5.7 129.0 (+2.5) 18.0 (<−2.5) 0.83 38.7 (+9.9) 19.0 (+0.9) 19.1 (+1)
BSA: body surface area; PV: pulmonary valve; MPA: main pulmonary artery. z-score according to Daubeney ([1], 284/id).
[3, 26, 27].Especiallycongenitalpulmonaryemphysemaand
MV and/or TV insuﬃciency are very common (speciﬁc)
in neonatal Marfan syndrome [3, 28]. The mutations are
located in the central region of the FBN1 gene (exons 24–
32) and all are de novo mutations. However, mutations of
patients with the classic form of Marfan syndrome have also
been found in this region [4, 6, 26, 28–36].
Clinically our patient had severe infantile Marfan syn-
drome, early diagnosed because of the symptoms of a large
ASD and VSD. We found a severely dilated pulmonary artery
before operation, due to a large left-to-right shunt and
pulmonary ﬂow hypertension. Although pulmonary artery
dilatation is a common ﬁnding in patients of all ages with
MFS [37, 38], this case illustrates that the main pulmonary
artery can dilate extremely due to increased pulmonary
arterypressureandﬂowwhichappearedtobereversibleafter
normalization of pulmonary artery pressure. In contrast,
the aortic root showed progressive dilatation after shunt
closure and improvement of left ventricular cardiac output.
Congenital heart disease in MFS is rare and only a few cases
have been described in literature [2, 4, 39–52]. Patent ductus
a r t e r i o s u sa n da t r i a ls e p t a ld e f e c th a v eb e e nd e s c r i b e di n
4–6% of the patients [2, 4, 39, 41, 44, 47, 51]a n dm a y
need surgical or interventional closure. The use of septal
occluders should be considered with caution in the Marfan
syndrome, because of risk of penetration [47]. An isolated
VSD, without complex heart defect, as in our patient, has
beenreportedinonly5cases(infantsandadults)inliterature
over the last 40 years [39–41, 46, 50, 52]. Coarctation of
the aorta was reported once in a 10-year-old girl [45].
Three cases with complex congenital heart disease were
described [42, 48, 49]. Congenital heart disease appears to
be more common in Beals-Hecht syndrome or congenital
contractural arachnodactyly (CCA), a dominantly inherited
disorder of connective tissue characterized by multiple
contractures, arachnodactyly, dolichostenomelia, scoliosis,
and external ear anomalies, with mutations in FBN2 gene
[53, 54]. Skeletal features are almost the same as in Marfan
syndrome, and dilatation of the aortic root and mitral valve
prolapse, although less common, can also occur in CCA. The
congenital heart defects described in CCA are very similar to
those in MFS, including ASD, VSD, patent ductus arteriosus,
coarctation, or interruption of the aorta [55, 56].
4. Conclusion
This special case of infantile MFS with congenital heart
disease demonstrates severe dilatation of both great arter-
ies with reversibility of pulmonary artery dilatation after
normalization of the pulmonary artery pressure. It further
illustratesthattheclinicalphenotypesofMFSandCCAshow
signiﬁcant overlap and that genetic testing was required for
ﬁnal diﬀerentiation.
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